Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Med Chem Lett ; 26(19): 4775-4780, 2016 10 01.
Article in English | MEDLINE | ID: mdl-27578247

ABSTRACT

During the lead generation and optimization of PARP inhibitors blocking centrosome clustering, it was discovered that increasing hydrogen bond acceptor (HBA) strength improved cellular potency but led to elevated Caco2 and MDR1 efflux and thus poor oral bioavailability. Conversely, compounds with lower efflux had reduced potency. The project team was able to improve the bioavailability by reducing efflux through systematic modifications to the strength of the HBA by changing the electronic properties of neighboring groups, whilst maintaining sufficient acceptor strength for potency. Additionally, it was observed that enantiomers with different potency showed similar efflux, which is consistent with the promiscuity of efflux transporters. Eventually, a balance between potency and low efflux was achieved for a set of lead compounds with good bioavailability which allowed the project to progress towards establishing in vivo pharmacokinetic/pharmacodynamic relationships.


Subject(s)
Centrosome/metabolism , Poly(ADP-ribose) Polymerase Inhibitors/pharmacokinetics , Administration, Oral , Animals , Biological Availability , Caco-2 Cells , Dogs , Humans , Hydrogen Bonding , Madin Darby Canine Kidney Cells , Mice , Poly(ADP-ribose) Polymerase Inhibitors/administration & dosage , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...